Anil Dasu is listed as a director on 1 SEC Form D filing by 1 issuer in May 2024: Nectero Medical Inc (Tempe, AZ — biotechnology — 2024; $32.8M reported sold to 31 investors).
What this means One deal on file with the SEC, filed May 2024. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Bruce Roberts (1 shared filing), Bryan Ziegler (1 shared filing), Colin Morrison (1 shared filing), Jack Springer (1 shared filing) and Robert Whirley (1 shared filing).
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Anil. Each name links to their own page.
The issuer belongs to the sponsor group Nectero (2 issuers, $33.5M reported sold, 2020–2024).
What this means A sponsor group is one team that sets up a new company for each deal. Nectero has 2 companies on file and $33.5M reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 2 court cases matching the name, 1 bankruptcy case matching the name listed in Key records below.
What this means 3 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 1 public filing for Anil Dasu and found 4 differences: Anil Dasu appears on 1 deal that stopped filing before reaching its target; Form D filed 36 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.